Cancers, Pain
6
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
67%
4 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Impact of Daily Oral Cannabis Doses in Patients With Cancer
Improving Cancer Pain Management Using AHCPR Cancer Pain Guidelines
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients: A Pilot Study
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy